Sunshine Biopharma Inc (OTCMKTS:SBFM) Is Today's OTC Focus

Shares of Sunshine Biopharma Inc (OTCMKTS:SBFM) exploded higher at the end of 2015 after acquiring all of the remaining rights, title and interest in and to all worldwide patents for the company’s Adva-27a anticancer compound. The Patent Purchase Agreement provided SBFM with direct ownership of all issued and pending Adva-27a related patents, which included all rights to this intellectual property worldwide. Prior, SBFM had ownership of only the U.S. patent. The purchase price paid by SBFM for the patent rights was $12,822,499, which will be paid pursuant to the terms of a secured promissory note, with quarterly payments of principal and interest due through December 2020.Adva-27a is SBFM’s lead anticancer compound, a Topoisomerase II inhibitor, small molecule that has recently been shown to be effective at killing Pancreatic Cancer cells, Multidrug Resistant Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935. The Company is planning Phase I clinical trials of Adva-27a for Pancreatic Cancer and in parallel Multidrug Resistant Breast Cancer to be conducted at McGill University’s Jewish General Hospital in Montreal (Canada). In October, SBFM had acquired just the US rights to the drug. Obviously the company is pretty excited about Adva-27a and its potential.To keep the ball rolling, Sunshine Biopharma announced last month that it is moving forward with its plans for the development of Adva-27a. In addition, the company said that it is currently in discussions with several investment groups for the purposes of securing funding for Adva-27a development through Phase I clinical trials. Adva-27a has proven to be effective at killing Multidrug Resistant Cancer cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells and Uterine Sarcoma cells (Results published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Of course, it all really comes down to the efficacy of Adva-27a. So far, what we’re seeing is positive. According to NCBI:

BACKGROUND/AIM:

Multidrug resistance poses a serious challenge in cancer therapy. To address this problem, we designed and synthesized Adva-27a, a novel non-ester GEM-difluorinated C-glycoside derivative of podophyllotoxin.

MATERIALS AND METHODS:

Adva-27a activity was evaluated in a variety of assays including inhibition of topoisomerase IIα, cytotoxic activity in drug-sensitive and drug-resistant cancer cell lines, metabolic stability in human liver microsomes and pharmacokinetic properties in rats.

RESULTS:

Adva-27a exhibited dose-dependent human topoisomerase IIα inhibitory activity and dose-dependent growth inhibitory activity in several drug-sensitive and two multidrug-resistant cancer cell lines. In the multidrug-resistant cell lines, MCF-7/MDR (breast cancer) and H69AR (small-cell lung cancer), Adva-27a was significantly more potent than etoposide. The metabolic stability of Adva-27a in human liver microsomes and its pharmacokinetic properties in rats were better than those of etoposide.

CONCLUSION:

Our studies have identified Adva-27a as a novel topoisomerase II inhibitor with superior cytotoxic activity against multidrug-resistant human cancer cells and more desirable pharmacokinetic properties than etoposide.

If we look at the $12.8 million being paid for the rights and then look at SBFM’s current market cap of just $1.87 million, it doesn’t take a rocket scientist to figure out that there’s big potential with SBFM shares. Furthermore, the deal was done with Advanomics, which owns 23% of SBFM. Obviously, Advanomics sees the value in having the IP in the public company versus retaining it all for themselves. This is good news for SBFM shareholders.Adva-27a has the potential to be a blockbuster drug. The next step for Sunshine Biopharma is securing funding to advance the drug's development. We foresee some smart money getting behind SBFM and moving things along. We just hope CEO Dr. Steve Silaty gets equity investors to fund the development at current levels and not engage in any toxic death spiral financings that will sink the company. We will be updating Insider Financial as soon as we know more. For continuing coverage on SBFM and our other hot stock picks, sign up to Insider Financial today and get our next hot stock pick!Disclosure: We have no position in SBFM and have not been compensated for this article.